Bought 25,000 @0.19Until this gets approval or a JV, the stock will remain low. However, the science appears to be better than Keytruda, which is already approved, so let's hope the results lead to a good 2024... Cash burn will be key, as the cost of capital has increased with the higher interest rates. Here we go.